Breaking the barrier in stroke: What Should we know? A mini-review

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3615-3623

  Borlongan, Cesar V ^a   Rodrigues, Antonio A ^a,b   Oliveira, Maria Carolina ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bioavailability; Central nervous system; Cerebral ischemia; Pathology; Permeability; Therapy

Indexed keywords

BIOLOGICAL MARKER; FLAVONOID; MANNITOL; MATRIX METALLOPROTEINASE;

ANGIOGENESIS; BLOOD BRAIN BARRIER; CELL DEATH; CELL SURVIVAL; CELL THERAPY; CELL TRACKING; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; DEGENERATIVE DISEASE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; KNOWLEDGE; MEDICAL RESEARCH; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCIENTIST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH;

EID: 84867567497     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002670     Document Type: Review

References (43)

1. Miyakawa T. Vascular pathology in Alzheimer's disease. Ann N Y Acad Sci, 2002; 977: 303-5.
2. Monahan AJ, Warren M, Carvey PM. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant, 2008; 17: 363-72.
3. Ronaldson TR and Davis TP. Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be targeted for Novel Therapeutic Approaches in Stroke. Curr Pharm Des 2012; 18(25): 3624-44.
4. Yasuhara T, Hara K, Maki M, et al. Mannitol facilitates neurotrophic factor upregulation and behavioural recovery in neonatal hypoxic-ischaemic rats with human umbilical cord blood grafts. J Cell Mol Med, 2010; 14: 914-921.
5. Ronaldson PT, Finch JD, DeMarco KM, Quigley CE, Davis TP. Inflammatory Pain Signals an Increase in Functional Expression of Organic Anion Transporting Polypeptide 1a4 at the Blood-Brain Barrier. J Pharm Exp Ther, 2011; 336: 827-39.
6. Ronaldson PT, DeMarco KM, Sanchez-Covarrubias L, Solinsky CM, Davis TP. Transforming growth factor signaling alters substrate permeability and tight junction protein expression at the blood'brain barrier during inflammatory pain. J Cereb Blood Flow Metab, 2009; 29: 1084-98.
7. Seo JH, Guoa S, Lok J, Navaratnan D, Kim KW, Lo EH. Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier. Curr Pharm Des 2012; 18(25): 3645-48.
8. Park KP, Rosell A, Foerch C, et al. Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke, 2009; 40: 2836-2842.
9. Wang X, Jung JC, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci, 2000; 20: 7037-42.
10. Tejima E, Guo S, Murata Y, et al. Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma, 2009; 26: 1935-41.
11. Guo S, Stins M, Ning M, Lo E. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis, 2010; 30: 290-6.
12. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med, 2003; 9: 1313-7.
13. Yamashita A and Abe K. Mechanisms of endogenous endothelial repair in stroke. Curr Pharm Des 2012; 18(25): 3649-52.
14. Yamashita T, Deguchi K, Nagotani S, Abe K. Vascular protection and restorative therapy in ischemic stroke. Cell Transplant, 2011; 20: 95-7.
15. Takamiya M, Miyamoto Y, Yamashita T, Deguchi K, Ohta Y, Ikeda Y, Matsuura T, Abe K. Neurological and pathological improvements of cerebral infarction in mice with platinum nanoparticles. J Neurosci Res, 2011.
16. Liu S, Agalliu D, Chuanhui Y, Fisher M. The Roles of Pericytes in Blood-Brain Function and Stroke. Curr Pharm Des 2012; 18(25): 3653-62.
17. Fisher M, French S, Ji P, Kim RC. Cerebral Microbleeds in the Elderly. Stroke, 2010; 41: 2782-5.
18. Fisher M. Pericyte signaling in the neurovascular unit. Stroke, 2009; 40: S13-5.
19. Tajiri N, Glover LE, Shinozuka K, Kaneko Y, van Loveren H, Borlongan CV. Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection. Curr Pharm Des 2012; 18(25): 3663-9.
20. Hess DC, Glover LE, Sanberg PR, Borlongan CV. Permeating the blood brain barrier and abrogating the inflammation in stroke: Implications for stroke therapy. Curr Pharm Des 2012; 18(25): 3670-76.
21. Borlongan CV, Hadman M, Davis Sanberg C, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke, 2004; 35: 2385-9.
22. Ishrat T, Soliman S, Guan W, Saler M, Fagan S. Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke. Curr Pharm Des 2012; 18(25): 3677-84.
23. Group Nt-PSS. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke, 1997; 28: 2109-18.
24. Switzer JA, Hess DC, Ergul A, et al. Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke. Stroke, 2011; 42: 2633-5.
25. Machado LS, Sazonova IY, Kozak A, et al. Minocycline and tissue-type plasminogen activator for stroke. Stroke, 2009; 40: 3028-33.
26. Manley NC and Steinberg GK. Tracking Stem Cells for Cellular Therapy in Stroke. Curr Pharm Des 2012; 18(25): 3685-93.
27. Gera A, Steinberg GK, Guzman R. In vivo neural stem cell imaging: current modalities and future directions. Regen Med, 2010; 5: 73-86.
28. Maher P, Salgado KF, Zivin JA, Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res, 2007; 1173: 117-25.
29. Lapchak PA, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15 lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience, 2007; 150: 585-91.
30. Lapchak PA. A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke. Curr Pharm Des 2012; 18(25): 3694-703.
31. Kaneko Y, Tajiri N, Shinozuka K, Glover LE, Weinbren N, Cortes L, Borlongan CV. Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells. Cur Pharm Des 2012; 18(25): 3731-4.
32. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The Great Migration of Bone Marrow-Derived Stem Cells Toward the Ischemic Brain: Therapeutic Implications for Stroke and Other Neurological Disorders. Prog Neurobiol, 2011.
33. Borlongan C. Bone marrow stem cell mobilization in stroke: a bonehead may be good after all! Leukemia, 2011.
34. Chopp M, Steinberg GK, Kondziolka D, et al. Who's in favor of translational cell therapy for stroke: STEPS forward please? Cell Transplant, 2009;18: 691-693.
35. Borlongan CV. Cell therapy for stroke: remaining issues to address before embarking on clinical trials. Stroke, 2009; 40: S146-8.
36. Borlongan CV, Weiss MD. Baby STEPS: a giant leap for cell therapy in neonatal brain injury. Pediatr Res, 2011;70: 3-9.
37. Hu X, Zhang M, Leak RK, Gana Y, Li P, Gao Y, Chen J. Delivery of Neurotherapeutics across the Blood Brain Barrier in Stroke. Curr Pharm Des 2012; 18(25): 3704-20.
38. Cao G, Pei W, Ge H, et al. In vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci, 2002; 22: 5423-31.
39. Zhang F, Signore AP, Zhou Z, Wang S, Cao G, Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J Neurosci Res, 2006; 83: 1241-51.
40. Yin W, Cao G, Johnnides MJ, et al. TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis, 2006; 21: 358-71.
41. Cho S. CD36 as a therapeutic target for endothelial dysfunction in stroke. CurrPharm Des 2012; 18(25): 3721-30.
42. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem, 2007; 282: 4634.
43. Cho S, Kim E. CD36: A multi'Äêmodal target for acute stroke therapy. J Neurochem, 2009; 109: 126-32.